AlphaID™
AT HOME

FDA-Cleared

AlphaID™ At Home Genetic Health Risk Service

Screening for people to determine their risk for genetic COPD, a condition known as alpha$_1$-antitrypsin deficiency, or AATD — from Grifols, the leader in alpha-1 detection

AlphaID At Home Service empowers people to screen themselves for alpha-1 from their homes at no cost to you, your patients, or their insurers

The AlphaID At Home Genetic Health Risk Service, including the kit, is provided for free and may not be billed to patients or their insurers. There is no obligation to purchase or use any product or service offered by any manufacturer.

GRIFOLS

AlphaID At Home Service

AlphaID At Home empowers people to determine their alpha-1 risk in the comfort of their homes

AlphaID At Home Saliva Collection Kit

Empowers people to screen for alpha-1
from the convenience of their home

AlphaID At Home Genetic Health Risk Service Report

Allows people to determine their risk for alpha-1
and encourages them to discuss results with an HCP

AlphaID At Home utilizes the same cheek swab and genotype test as the AlphaID kit healthcare providers have used for years to screen patients in the office

- A free*, FDA-cleared, at-home genetic service that allows individuals to find out their risk level for alpha-1 with **at least 99% accuracy**[1,2]
- AlphaID At Home detects **14 genetic variants linked to 95%** of alpha-1 cases[2,3]
- Determines if genetics increases a person's risk of developing lung and/or liver disease linked to alpha-1 compared to the general population[4]
- Confidential HIPAA-compliant results
- Encourages a follow-up discussion with their HCP

People can screen for alpha-1 with AlphaID At Home

3 steps to confidential and comprehensive test results:

1

Order a kit at AlphaIDAtHome.com

2

Swab their cheeks at home and **send the sample** off to the laboratory in the prepaid envelope

3

Receive their results report via confidential patient portal

May **bring the results report to their HCP** for further interpretation

The kit, postage, and lab processing are all paid for by Grifols—no payment or insurance information will be required at any time

To learn more about the screening journey with AlphaID At Home, visit AlphaIDAtHome.com

*The AlphaID At Home Genetic Health Risk Service, including the kit, is provided for free and may not be billed to patients or their insurers. There is no obligation to purchase or use any product or service offered by any manufacturer.

Understanding the AlphaID At Home Genetic Health Risk Service Report

Interpreting the report that determines a person's risk level for alpha-1

View their results on page 3 of the report



What the test determines—

- Alpha-1 allele variant type
- Risks for lung and/or liver disease associated with these variants

People should be encouraged to share the results with their healthcare professional, regardless of the result.

AlphaID At Home detects 14 genetic variants associated with alpha-1 **with at least 99% accuracy**:[2]

- **Most common normal allele:** M[3]
- **Most common deficient alleles:** S, Z, F, I[3,5]
- **Less common deficient alleles:** M Heerlen, M Malton, M Nichinan, M Palermo, M Procida, P Lowell, S Iiyama, Y Barcelona[5-10]

If increased risk for alpha-1 is detected, AlphaID™ CONFIRM can be used by healthcare professionals to verify alpha-1

AATD, alpha$_1$-antitrypsin deficiency.

Confirm the diagnosis with AlphaID CONFIRM

Provides confirmation of an alpha-1 diagnosis in people at increased risk

Confirms the genotype and reports the alpha$_1$-antitrypsin serum level

Reports risk level for lung and liver disease linked with alpha-1

If the diagnosis is confirmed, consider discussing available treatment options with people who have severe alpha-1

Grifols: Committed to supporting the alpha-1 community

As the **leader in alpha-1 screening for more than 30 years**, Grifols is dedicated to advancing the understanding of and screening process for alpha-1

Frequently Asked Questions

Q: I heard Grifols received FDA-clearance for an at home alpha-1 test. What is it?

A: AlphaID At Home Genetic Health Risk Service enables US adults to screen for their genetic risk of alpha$_1$-antitrypsin deficiency (alpha-1) using a cheek swab device without a prescription from a healthcare professional.

Q: How and/or when can consumers order?

A: Any consumer 18 years of age or older in the US will be able to go to www.AlphaIDAtHome.com and order a kit to learn their risk for alpha-1.

Q: What does an AlphaID At Home screening result look like?

A: The AlphaID At Home report offers an easy-to-understand indication of the genotype, reports any variants detected, and provides the risk level for lung and liver disease linked to alpha-1.

Q: Is there a website where I can learn more?

A: Visit AlphaID.com to obtain additional information about the completely free, fast, and accurate Grifols suite of innovative screening tools for alpha-1.

Q: A patient has brought an AlphaID At Home screening result. What are the next steps?

A: If you determine that your patient has a positive result for an abnormal variant, confirm the diagnosis of alpha-1 with AlphaID™ CONFIRM, a free test available at AlphaID.com that verifies the genotype and reports the alpha$_1$-antitrypsin serum level.

Scan here to learn more about the Grifols AlphaID program

To help your patients with COPD learn more about uncovering their risk for AATD, visit GeneticCOPD.com

References: 1. "Grifols Receives FDA Clearance for AlphaID™ At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1." Grifols press release. 2022. **2.** A1AT Genotyping Test. Package insert. Progenika Biopharma; 2017. **3.** Stoller JK, Hupertz V, Aboussouan LS. Alpha1 antitrypsin deficiency. In: Adam MP, Everman DB, Mirzaa GM, et al, editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Accessed March 31, 2023. https://www.ncbi.nlm.nih.gov/books/NBK1519/ **4.** AlphaID™ At Home Genetic Health Risk Service Package Insert. Grifols; 2022. **5.** Lopez-Campos JL, Casas-Maldonado F, Torres-Duran M, et al. Results of a diagnostic procedure based on multiplex technology on dried blood spots and buccal swabs for subjects with suspected alpha1 antitrypsin deficiency. *Arch Bronconeumol* (Engl Ed). 2021;57(1):42-50. **6.** Reid CL, Wiener GJ, Cox DW, Richter JE, Geisinger KR. Diffuse hepatocellular dysplasia and carcinoma associated with the Mmalton variant of α1-antitrypsin. *Gastroenterology*. 1987;93:181-187. **7.** Seixas S, Marques PI. Known mutations at the cause of alpha-1 antitrypsin deficiency: an updated overview of SERPINA1 Variation Spectrum. *Appl Clin Genet*. 2021;14:173–194. **8.** Foil KE. Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency. *Ther Adv Chronic Dis*. 2021;12:33-48. **9.** de la Roza C, Lara B, Vilá S, Miravittles M. α1-antitrypsin deficiency: situation in Spain and development of a screening program. *Arch Bronconeumol*. 2006;42(6):290-298. **10.** Miravitlles M. Alpha1-Antitrypsin Deficiency: Epidemiology and Prevalence. *Respiratory Medicine*. 2000;94(Suppl C):S12-S15.

AlphaID™ AT HOME

GRIFOLS

 April 2023 US-PRL-2300026